Previous 10 | Next 10 |
Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update PR Newswire STATEN ISLAND, N.Y. , March 6, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical...
--News Direct-- A New Gold Standard for C. diff Therapy Could be in the Offing; Next Data Release Expected in 2Q23 Clostridioides difficile/Clostridium difficile (C. diff) is a bacterial infection and is the most common cause of healthcare-associated diarrhea . C. ...
Acurx Pharmaceuticals CEO David Luci tells Soulstring Media Group why he thinks his company and lead drug candidate, Ibezapolstat, can be a front-line treatment against C. difficile New York, New York--(Newsfile Corp. - February 7, 2023) - Soulstring Media Group, Llc., a market research, aggrega...
(NewsDirect) By Faith Ashmore, Benzinga C. diff is a life-threatening bacterial infection that causes diarrhea and colitis, which is the inflammation of the colon. Approximately 600,000 are diagnosed with C. diff each year in the United States and it causes approximate...
Start Time: 08:30 End Time: 08:49 Acurx Pharmaceuticals, Inc. (ACXP) Q3 2022 Earnings Conference Call November 14, 2022, 08:30 AM ET Company Participants David Luci - President and CEO Robert Shawah - Co-Founder and CFO Conference Call Participants ...
Acurx Pharmaceuticals press release ( NASDAQ: ACXP ): Q3 GAAP EPS of -$0.32 misses by $0.04 . For further details see: Acurx Pharmaceuticals GAAP EPS of -$0.32 misses by $0.04
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2022 Results and Provides Business Update PR Newswire STATEN ISLAND, N.Y. , Nov. 14, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical st...
NEW YORK, Nov. 04, 2022 (GLOBE NEWSWIRE) -- FMW Media's New to The Street / Newsmax TV announces the broadcasting line-up of its nationally syndicated 1- hour TV show this Sunday, November 6, 2022, airing time 10-11 AM ET. New to The Street's 403rd TV episode f...
Acurx Pharmaceuticals, Inc. to Discuss 2022 Third Quarter Financial Results on November 14, 2022 Conference Call and Provide Business Update PR Newswire STATEN ISLAND, N.Y. , Nov. 1, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx"...
Acurx Announces Scientific Oral and Poster Presented at IDWeek 2022 PR Newswire Presents research on ibezapolstat's selective activity on healthy bacteria within the gut microbiome in the treatment of C. difficile Infection (CDI) Emerging ibezapolstat microbiom...
News, Short Squeeze, Breakout and More Instantly...
Acurx Pharmaceuticals Inc. Company Name:
ACXP Stock Symbol:
NASDAQ Market:
Acurx Pharmaceuticals Inc. Website:
USPTO Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving Health of the Gut Microbiome PR Newswire STATEN ISLAND, N.Y. , July 17, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:...
Acurx Pharmaceuticals, Inc. to Discuss Second Quarter 2024 Financial Results on August 9, 2024 Conference Call and Provide Business Update PR Newswire STATEN ISLAND, N.Y. , July 16, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "...
Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results for CDI at Scientific Conference PR Newswire Additional analyses of clinical and microbiological data from the Phase 2b segment show favorable gut microbiome changes including inc...